A Multicenter Phase 2, Single-Arm Open-Label Study of DCC-2618 to Assess Efficacy, Safety, and Pharmacokinetics In Patients With Advanced Gastrointestinal Stromal Tumors Who Have Progressed On Prior Anticancer Therapies.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ripretinib (Primary)
Indications Gastrointestinal stromal tumours
Focus Therapeutic Use
Acronyms bridging study
Sponsors ZAI Lab

Most Recent Events

06 Jun 2023 Results (data cut-off was 23 Aug 2022) assessing the long term efficacy and safety of ripretinib in patients with advanced gastrointestinal stromal tumors, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
26 Aug 2022 Status changed from active, no longer recruiting to completed.
10 Jun 2022 Results published in the Clinical Cancer Research

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight